Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products

Summary

Alteogen entered an option and license agreement with Novartis to develop and commercialize subcutaneous formulations utilizing its Hybrozyme platform technology. This is Alteogen's fourth licensing agreement signed in 2026, accelerating expansion of the platform.